MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ford, J. M.
Right arrow Articles by Hait, W. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ford, J. M.
Right arrow Articles by Hait, W. N.

Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance

JM Ford, WC Prozialeck and WN Hait

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510.

Phenothiazines and structurally related compounds inhibit cellular proliferation and sensitize multidrug-resistant (MDR) cells to chemotherapeutic agents. To identify more potent pharmaceuticals, we studied the structure-activity relationships of 30 phenothiazines and related compounds on cellular proliferation and MDR in sensitive MCF-7 and resistant MCF-7/DOX human breast cancer cells. Substitutions on the phenothiazine ring that increased hydrophobicity increased antiproliferative and anti-MDR activities. For example, -Cl and -CF3 groups increased whereas -OH groups decreased potency. Modifying the length of the alkyl bridge and the type of amino side chain also influenced potency. Compounds with increased activity against cellular proliferation and MDR possessed a four-carbon bridge rather than a three- or two-carbon bridge and a piperazinyl amine rather than a noncyclic amino group. Compounds with tertiary amines were better anti- MDR agents than those with secondary or primary amines but were equipotent antiproliferative agents. The effects of these substituents were unrelated to hydrophobicity. The structure-activity relationships suggest that an ideal phenothiazine structure for reversing MDR has a hydrophobic nucleus with a -CF3 ring substitution at position 2, connected by a four-carbon alkyl bridge to a para-methyl-substituted piperazinyl amine. We subsequently studied related compounds having certain of these properties. Substitution of a carbon for a nitrogen at position 10 of the tricyclic ring, with a double bond to the side chain (thioxanthene), further increased activity against MDR. For example, (trans)-flupenthixol, the most potent of these compounds, increased the potency of doxorubicin against MDR cells by 15-fold, as compared with its stereoisomer (cis)-flupenthixol (5-fold) or its phenothiazine homolog fluphenazine (3-fold). (cis)- and (trans)-flupenthixol were equipotent antiproliferative agents. (trans)-flupenthixol was not accumulated more than (cis)-flupenthixol in MDR cells, implying that their stereospecific anti-MDR effects were not the result of selective differences in the access of the drugs to intracellular targets. Both drugs increased the accumulation of doxorubicin in MDR cells, but not in sensitive cells, suggesting that they modulate MDR by interacting with a uniquely overexpressed cellular target in these resistant cells. The apparent lack of clinical toxicity of (trans)-flupenthixol makes it an attractive drug for further investigation.

Volume 35, Issue 1, pp. 105-115, 01/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
Y. Y. Chan, Y. M. Ong, and K. L. Chua
Synergistic Interaction between Phenothiazines and Antimicrobial Agents against Burkholderia pseudomallei
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 623 - 630.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. W. Elmore, X. Di, C. Dumur, S. E. Holt, and D. A. Gewirtz
Evasion of a Single-Step, Chemotherapy-Induced Senescence in Breast Cancer Cells: Implications for Treatment Response
Clin. Cancer Res., April 1, 2005; 11(7): 2637 - 2643.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Arora, J.-M. Yang, R. Utsumi, T. Okamoto, T. Kitayama, and W. N. Hait
P-Glycoprotein Mediates Resistance to Histidine Kinase Inhibitors
Mol. Pharmacol., September 1, 2004; 66(3): 460 - 467.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Maki, P. Hafkemeyer, and S. Dey
Allosteric Modulation of Human P-glycoprotein. INHIBITION OF TRANSPORT BY PREVENTING SUBSTRATE TRANSLOCATION AND DISSOCIATION
J. Biol. Chem., May 9, 2003; 278(20): 18132 - 18139.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
G. W. Kaatz, V. V. Moudgal, S. M. Seo, and J. E. Kristiansen
Phenothiazines and Thioxanthenes Inhibit Multidrug Efflux Pump Activity in Staphylococcus aureus
Antimicrob. Agents Chemother., February 1, 2003; 47(2): 719 - 726.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Ecker, M. Huber, D. Schmid, and P. Chiba
The Importance of a Nitrogen Atom in Modulators of Multidrug Resistance
Mol. Pharmacol., October 1, 1999; 56(4): 791 - 796.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
G. Klopman, L. M. Shi, and A. Ramu
Quantitative Structure-Activity Relationship of Multidrug Resistance Reversal Agents
Mol. Pharmacol., August 1, 1997; 52(2): 323 - 334.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
C. D. Smith and J. T. Zilfou
Circumvention of P-glycoprotein-mediated Multiple Drug Resistance by Phosphorylation Modulators Is Independent of Protein Kinases
J. Biol. Chem., November 24, 1995; 270(47): 28145 - 28152.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Zhang, C. W. Sachs, H.-W. Fu, R. L. Fine, and P. J. Casey
Characterization of Prenylcysteines That Interact with P-glycoprotein and Inhibit Drug Transport in Tumor Cells
J. Biol. Chem., September 29, 1995; 270(39): 22859 - 22865.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1989 by the American Society for Pharmacology and Experimental Therapeutics